Jane Huang
2018 - BeiGene, Ltd.
In 2018, Jane Huang earned a total compensation of $3.5M as Chief Medical Officer at BeiGene, Ltd., a 14% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $278,375 |
|---|---|
| Option Awards | $2,199,983 |
| Salary | $425,000 |
| Stock Awards | $549,851 |
| Other | $8,250 |
| Total | $3,461,459 |
Huang received $2.2M in option awards, accounting for 64% of the total pay in 2018.
Huang also received $278.4K in non-equity incentive plan, $425K in salary, $549.9K in stock awards and $8.3K in other compensation.
Rankings
In 2018, Jane Huang's compensation ranked 3,294th out of 14,244 executives tracked by ExecPay. In other words, Huang earned more than 76.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,294 out of 14,244 | 77th |
Division Manufacturing | 1,217 out of 5,765 | 79th |
Major group Chemicals And Allied Products | 421 out of 2,128 | 80th |
Industry group Drugs | 348 out of 1,817 | 81st |
Industry Pharmaceutical Preparations | 267 out of 1,391 | 81st |
Source: SEC filing on April 29, 2019.
Huang's colleagues
We found five more compensation records of executives who worked with Jane Huang at BeiGene, Ltd. in 2018.
2018
John Oyler
BeiGene, Ltd.
Chief Executive Officer
2018
Xiaobin Wu
BeiGene, Ltd.
General Manager of China and President
2018
Howard Liang
BeiGene, Ltd.
Chief Financial Officer
2018
Amy Peterson
BeiGene, Ltd.
Chief Medical Officer
2018
Hematology Peterson
BeiGene, Ltd.
Chief Medical Officer
News
Prelude Therapeutics CEO Krishna Vaddi's 2023 pay slips 20% to $2.6M
April 26, 2024
Prelude Therapeutics CEO Krishna Vaddi's 2022 pay falls 53% to $3.3M
April 28, 2023
BeiGene, Ltd. CEO John Oyler's 2019 pay falls 55% to $13M
April 28, 2020
BeiGene, Ltd. CEO John Oyler's 2018 pay jumps 171% to $28M
April 29, 2019